Patricia Pozo Rosich (Headache Unit and Headache Research Group, Vall d’Hebron University Hospital, Barcelona, Spain) talks to us about unmet needs of migraine prevention in Europe and the calcitonin gene-related peptide receptor antagonist, erenumab, in light of it recently receiving a positive CHMP opinion for this indication.
Questions
1. What are the major unmet needs of migraine prevention in Europe? (0:12)
2. What is the mechanism of action of erenumab? (0:50)
3. How is erenumab administered? (1:44)
4. Could you tell us a little about the evidence base for the positive CHMP opinion for erenumab for the prevention of migraine? (2:08)
5. Which patients are most likely to benefit from erenumab? (2:39)
Speaker disclosure: Patricia Pozo Rosich serves as a speaker/adviser for Allergan, Almirall, Chiesi, Novartis, Teva and Lilly; she also receives grant support from Allergan.
Filmed at the 4th Congress of the European Academy of Neurology (EAN), Lisbon, Portugal, June 2018.
